Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

Summary: Wave Life Sciences had a tough week. Their new obesity drug only helped people lose 1% of their body weight over six months. Because of this, their stock dropped by 50%. On the other hand, Kodiak Sciences had great news. Their new eye drug for diabetic vision loss succeeded in a major test, and their stock shot up by over 50%!

In other business news, Pinnacle Medicines raised $89 million to create new pill-based medicines. Also, Pulmatrix is joining forces with a company called Eos Senolytix to make drugs for muscle loss related to aging.

For more details, see rssapp-biopharmadive-com at biopharmadive.com/news/wave-obesity-kodiak-results-pinnacle-pulmatrix/815762/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-03-26%20BioPharma%20Dive%20[issue:83169]&utm_term=BioPharma%20Dive (opens in new tab)